Entropy Technologies LP Has $190,000 Holdings in Dynavax Technologies Corporation $DVAX
Entropy Technologies LP reduced its stake in Dynavax Technologies by 81.3% in Q2, now holding $190,000 worth of shares. Other institutional investors have also adjusted their positions. Analysts have mixed ratings on Dynavax, with a consensus 'Hold' rating and a price target of $24.33. The stock is trading at $11.43, with a market cap of $1.34 billion. Dynavax reported Q3 earnings of $0.21 per share, beating estimates. The company focuses on vaccines, including HEPLISAV-B for hepatitis B.
Entropy Technologies LP trimmed its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 81.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,185 shares of the biopharmaceutical company's stock after selling 83,649 shares during the quarter. Entropy Technologies LP's holdings in Dynavax Technologies were worth $190,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd bought a new position in shares of Dynavax Technologies during the second quarter worth approximately $121,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in Dynavax Technologies during the second quarter worth approximately $127,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Dynavax Technologies during the second quarter worth approximately $185,000. Creative Planning increased its stake in Dynavax Technologies by 27.7% during the 2nd quarter. Creative Planning now owns 113,127 shares of the biopharmaceutical company's stock worth $1,122,000 after acquiring an additional 24,568 shares during the period. Finally, Vise Technologies Inc. acquired a new position in Dynavax Technologies in the 2nd quarter valued at $231,000. Institutional investors own 96.96% of the company's stock.
Get Dynavax Technologies alerts:
Analyst Upgrades and Downgrades
DVAX has been the topic of several analyst reports. Weiss Ratings reissued a "sell (d)" rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, JMP Securities reiterated a "market outperform" rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $24.33.
View Our Latest Research Report on DVAX
Dynavax Technologies Trading Down 0.3%
Shares of Dynavax Technologies stock opened at $11.43 on Thursday. The firm's 50 day moving average is $10.38 and its 200 day moving average is $10.32. The firm has a market capitalization of $1.34 billion, a PE ratio of -24.85 and a beta of 1.09. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $14.63. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.
Dynavax Technologies Company Profile
(Free Report)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
- Five stocks we like better than Dynavax Technologies
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Gold Loves Trump as Much as Trump Loves Gold
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- What Are Dividends? Buy the Best Dividend Stocks
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Dynavax Technologies Right Now?
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
